Last reviewed · How we verify

strontium chloride hexahydrate

Smerud Medical Research International AS · Phase 3 active Small molecule

strontium chloride hexahydrate is a Small molecule drug developed by Smerud Medical Research International AS. It is currently in Phase 3 development. Also known as: 2PX.

At a glance

Generic namestrontium chloride hexahydrate
Also known as2PX
SponsorSmerud Medical Research International AS
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about strontium chloride hexahydrate

What is strontium chloride hexahydrate?

strontium chloride hexahydrate is a Small molecule drug developed by Smerud Medical Research International AS.

Who makes strontium chloride hexahydrate?

strontium chloride hexahydrate is developed by Smerud Medical Research International AS (see full Smerud Medical Research International AS pipeline at /company/smerud-medical-research-international-as).

Is strontium chloride hexahydrate also known as anything else?

strontium chloride hexahydrate is also known as 2PX.

What development phase is strontium chloride hexahydrate in?

strontium chloride hexahydrate is in Phase 3.

Related